All In Biotech

NDA 022272 · Knoa Pharma

Oxycontin

Oxycodone Hydrochloride · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Apr 5, 2010

Approved uses

3

Original approval plus efficacy supplements

Registered trials

646

137 Phase 3, 50 recruiting

FAERS reports

212,313

191,923 serious, 51,687 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCONTIN Addiction, Abuse, and Misuse Because the use of OXYCONTIN exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of OXYCONTIN, especially during initiation or following a dosage increase . To reduce the risk of respiratory depression, proper dosing and titration of OXYCONTIN are essential. Instruct patients to swallow OXYCONTIN tablets whole; crushing, chewing, or dissolving OXYCONTIN tablets can cause rapid release and absorption of a potentially fatal dose of...

What it is approved for

From the label in effect Jun 24, 2026.

OXYCONTIN is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids, in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including OXYCONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCONTIN is not indicated as an as-needed (prn) analgesic. OXYCONTIN is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic that cannot be adequately treated with alternative options, including immediate-release opioids in: Adults ( 1 ); and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including OXYCONTIN, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) OXYCONTIN is not indicated as an as-needed (prn) analgesic. ( 1 )

Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 20MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 60MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 15MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 80MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • OXYCONTIN · OXYCODONE HYDROCHLORIDE 40MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.

All 646 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence99,796
  • pain56,002
  • overdose48,881
  • emotional distress48,435
  • drug withdrawal syndrome36,832
  • death23,538
  • toxicity to various agents14,059
  • drug abuse7,961
  • anxiety7,906
  • depression7,847
  • nausea7,618
  • drug ineffective6,902

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,787
20053,139
20061,574
20072,484
20081,561
20091,630
20102,800
20112,650
20122,872
20132,586
20143,448
20154,752
20165,867
20177,127
201828,072
20195,550
202025,216
202153,552
202234,329
20235,766
20244,779
20255,148
20263,621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oxycontin (Oxycodone HCl)

2024 spending

$338M

Beneficiaries

61,465

474,072 claims

Per beneficiary

$5,495

$11.30 per unit

View as table
YearSpending
2020$558,686,954
2021$453,164,731
2022$416,084,689
2023$390,573,654
2024$337,754,323

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,204 on PubMed

Sponsor: Knoa Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.